Vanguard Group Inc. Raises Holdings in Guardant Health, Inc. (NASDAQ:GH)

Vanguard Group Inc. boosted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 1.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,950,230 shares of the company’s stock after buying an additional 146,902 shares during the quarter. Vanguard Group Inc. owned approximately 9.28% of Guardant Health worth $324,565,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. CWM LLC boosted its stake in Guardant Health by 137.1% in the third quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after acquiring an additional 569 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in Guardant Health in the third quarter valued at approximately $35,000. Acadian Asset Management LLC acquired a new stake in Guardant Health in the first quarter valued at approximately $37,000. Captrust Financial Advisors boosted its stake in Guardant Health by 33.2% in the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock valued at $44,000 after acquiring an additional 271 shares in the last quarter. Finally, Belpointe Asset Management LLC boosted its stake in Guardant Health by 33.3% in the first quarter. Belpointe Asset Management LLC now owns 3,049 shares of the company’s stock valued at $71,000 after acquiring an additional 761 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wolfe Research started coverage on shares of Guardant Health in a research note on Wednesday, December 13th. They issued a “peer perform” rating for the company. The Goldman Sachs Group dropped their price objective on shares of Guardant Health from $43.00 to $37.00 and set a “buy” rating on the stock in a report on Monday, January 29th. JPMorgan Chase & Co. dropped their price objective on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Piper Sandler dropped their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. Finally, Guggenheim started coverage on shares of Guardant Health in a report on Thursday, December 14th. They set a “neutral” rating on the stock. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $41.30.

Insiders Place Their Bets

In other news, insider Kumud Kalia acquired 2,187 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the transaction, the insider now owns 12,722 shares in the company, valued at approximately $226,706.04. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 6.20% of the company’s stock.

Guardant Health Price Performance

NASDAQ:GH opened at $17.96 on Thursday. Guardant Health, Inc. has a one year low of $16.92 and a one year high of $41.06. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -4.20 and a beta of 0.87. The firm’s fifty day moving average is $20.62 and its two-hundred day moving average is $24.46.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.65). Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. The business had revenue of $155.05 million during the quarter, compared to analysts’ expectations of $151.71 million. Research analysts expect that Guardant Health, Inc. will post -3.49 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.